GlassScriptPhysician profile
Eileen Marie Widrick
NPI 1083800874
$6,852.40
in general payments reported to CMS, 2019-2025
28 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,027 · 2022: $795 · 2023: $1,452 · 2024: $2,166 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,921 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,921.35 |
| Education | $109.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,431.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,292.93 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $734.72 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $605.93 | 2022-2025 | |
| Esperion Therapeutics, INC. | $398.12 | 2021 | |
| Glaxosmithkline, LLC. | $377.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $269.38 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.52 | 2024-2025 | Trintellix |
| Astellas Pharma US INC | $210.18 | 2023-2024 | Veozah, Myrbetriq |
| Dexcom, INC. | $209.35 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Exact Sciences Corporation | $167.75 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $132.25 | 2022-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $127.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.32 | 2022-2024 | Jardiance, Tradjenta |
| Phathom Pharmaceuticals, INC. | $93.39 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $80.53 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $66.42 | 2021-2023 | Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $52.58 | 2025 | |
| Idorsia Pharmaceuticals US INC | $48.51 | 2022-2024 | Quviviq |
| Corcept Therapeutics | $39.59 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $26.29 | 2024 | Gemtesa |
| Csl Behring | $24.23 | 2025 | Haegarda |
| Alk-Abello, INC | $22.45 | 2023 | Grastek, Ragwitek, Odactra |
| Genentech USA, INC. | $21.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $20.19 | 2025 | Zoryve |
| Abbott Laboratories | $18.28 | 2023 | Freestyle Libre 3 |
| Philips North America LLC | $17.08 | 2025 | Respiratory |
| Tolmar, INC. | $15.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Widrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.